TW202325343A - 去醣基化抗體之放射性複合體,及放射性醫藥 - Google Patents

去醣基化抗體之放射性複合體,及放射性醫藥 Download PDF

Info

Publication number
TW202325343A
TW202325343A TW111132932A TW111132932A TW202325343A TW 202325343 A TW202325343 A TW 202325343A TW 111132932 A TW111132932 A TW 111132932A TW 111132932 A TW111132932 A TW 111132932A TW 202325343 A TW202325343 A TW 202325343A
Authority
TW
Taiwan
Prior art keywords
antibody
complex
radioactive
group
amino acid
Prior art date
Application number
TW111132932A
Other languages
English (en)
Chinese (zh)
Inventor
岸本聡
武田拓也
成田雄大
河谷稔
井澤彰宏
水勇太
Original Assignee
日商日本醫事物理股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本醫事物理股份有限公司 filed Critical 日商日本醫事物理股份有限公司
Publication of TW202325343A publication Critical patent/TW202325343A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111132932A 2021-08-31 2022-08-31 去醣基化抗體之放射性複合體,及放射性醫藥 TW202325343A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-141625 2021-08-31
JP2021141625 2021-08-31

Publications (1)

Publication Number Publication Date
TW202325343A true TW202325343A (zh) 2023-07-01

Family

ID=85411332

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132932A TW202325343A (zh) 2021-08-31 2022-08-31 去醣基化抗體之放射性複合體,及放射性醫藥

Country Status (6)

Country Link
US (1) US20240316228A1 (cg-RX-API-DMAC7.html)
EP (1) EP4397320A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023033022A1 (cg-RX-API-DMAC7.html)
CN (1) CN118159305A (cg-RX-API-DMAC7.html)
TW (1) TW202325343A (cg-RX-API-DMAC7.html)
WO (1) WO2023033022A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022080481A1 (cg-RX-API-DMAC7.html) * 2020-10-16 2022-04-21
CA3215787A1 (en) * 2021-03-31 2022-10-06 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
JPWO2022224980A1 (cg-RX-API-DMAC7.html) * 2021-04-20 2022-10-27
AU2024234975A1 (en) * 2023-03-15 2025-09-18 Kagoshima University Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP6872181B2 (ja) 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
EP3418304B1 (en) 2016-02-15 2021-08-04 Kanagawa Prefectural Hospital Organization Recognition of membrane type mucin-like protein and clinical application thereof
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
JP2021506842A (ja) * 2017-12-18 2021-02-22 ヤンセン バイオテツク,インコーポレーテツド ポリペプチドの放射性標識
TW202504917A (zh) 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
ES3075769T3 (en) * 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
PH12022550894A1 (en) * 2019-10-18 2023-03-27 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN114555132A (zh) * 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
JP7291797B2 (ja) 2019-10-18 2023-06-15 住友ファーマ株式会社 ヒト化抗体およびその使用方法
JP7680745B2 (ja) 2019-10-24 2025-05-21 国立大学法人 鹿児島大学 1価ccap生成物の製造方法
JP6827224B1 (ja) 2020-02-29 2021-02-10 隆一 嶋田 通信回線を利用した電力系統安定化システム

Also Published As

Publication number Publication date
WO2023033022A1 (ja) 2023-03-09
EP4397320A4 (en) 2026-08-12
CN118159305A (zh) 2024-06-07
US20240316228A1 (en) 2024-09-26
EP4397320A1 (en) 2024-07-10
JPWO2023033022A1 (cg-RX-API-DMAC7.html) 2023-03-09

Similar Documents

Publication Publication Date Title
JP7679326B2 (ja) Ri標識されたヒト化抗体
TWI875842B (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
EP4397320A1 (en) Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product
WO2023277144A1 (ja) Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体
EP4609881A1 (en) Radioactive pharmaceutical composition
EP4327831A1 (en) Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
CN116456992A (zh) 抗her2抗体的放射性复合物和放射性药物
EP4480502A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
US20240207463A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
TW202233247A (zh) 抗her2抗體之放射性複合體及放射性醫藥
CN117769440A (zh) 抗cd20抗体的放射性复合物和放射性药物
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство
KR20230174238A (ko) 방사성 항종양제
HK40092772A (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
EA051630B1 (ru) Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство
CN117377690A (zh) 抗egfr抗体的放射性复合物和放射性药物
EA050695B1 (ru) Способ получения антитела, меченного радиоактивным металлом